Funder: National Institutes of Health

Due Dates: May 21, 2025 (Letter of Intent) | June 20, 2025 (Application) | September 7, 2025 (AIDS) | October 20, 2025 (Application) | January 7, 2026 (AIDS) | February 20, 2026 (Application) | May 7, 2026 (AIDS) | June 22, 2026 (Application) | September 7, 2026 (AIDS) | October 20, 2026 (Application) | January 7, 2027 (AIDS) | February 22, 2027 (Application) | May 7, 2027 (AIDS) | June 21, 2027 (Application) | September 7, 2027 (AIDS) | October 20, 2027 (Application) | January 7, 2028 (AIDS) | January 8, 2028 (Expiration)

Funding Amounts: No budget cap; budgets must reflect actual needs. Project period: up to 5 years (R61: 1–3 years, R33: 1–3 years).

Summary: Supports phased development and initial clinical validation of biomarkers or composite biomarkers for neurological and neuromuscular disorders to improve clinical trials and clinical care.

Key Information: Animal studies are not allowed; preliminary human evaluation is required. Contact NIH if requesting ≥$500,000 direct costs in any year.